Profile data is unavailable for this security.
About the company
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
- Revenue in USD (TTM)0.00
- Net income in USD-116.20m
- Incorporated2015
- Employees150.00
- LocationNkarta Inc1150 Veterans BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (925) 407-1049
- Fax+1 (302) 655-5049
- Websitehttps://www.nkartatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomea Fusion Inc | 0.00 | -127.27m | 444.63m | 110.00 | -- | 3.28 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| PepGen Inc | 0.00 | -78.63m | 453.14m | 64.00 | -- | 3.07 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 455.98m | 99.00 | -- | 2.23 | -- | 7.41 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | -- | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 459.42m | 19.00 | -- | 4.66 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -66.39m | 460.25m | 58.00 | -- | 3.28 | -- | -- | -2.69 | -2.69 | 0.00 | 4.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0153 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 461.21m | 162.00 | -- | 1.35 | 303.83 | 3.87 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Nkarta Inc | 0.00 | -116.20m | 461.56m | 150.00 | -- | 0.9743 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Korro Bio Inc | 0.00 | -81.17m | 464.10m | 101.00 | -- | 2.36 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Editas Medicine Inc | 69.41m | -166.13m | 467.09m | 265.00 | -- | 1.59 | -- | 6.73 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| ACELYRIN Inc | 0.00 | -381.64m | 467.86m | 130.00 | -- | 0.7053 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Cibus Inc | 2.32m | -285.67m | 468.82m | 183.00 | -- | 1.43 | -- | 202.08 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| Entrada Therapeutics Inc | 162.87m | 23.49m | 479.04m | 160.00 | 22.62 | 1.77 | 17.88 | 2.94 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 479.70m | 127.00 | -- | 6.04 | -- | 95.94 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 480.31m | 181.00 | -- | 1.13 | -- | 74.14 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Taysha Gene Therapies Inc | 15.45m | -111.57m | 480.64m | 52.00 | -- | 6.41 | -- | 31.11 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Data as of May 15 2024. Currency figures normalised to Nkarta Inc's reporting currency: US Dollar USD
38.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 27 Mar 2024 | 13.85m | 18.90% |
| Adage Capital Management LPas of 31 Dec 2023 | 3.45m | 4.71% |
| Commodore Capital LPas of 31 Dec 2023 | 2.73m | 3.73% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.50m | 3.42% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.93m | 2.64% |
| Wasatch Advisors, Inc.as of 31 Mar 2024 | 1.17m | 1.60% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 657.77k | 0.90% |
| Geode Capital Management LLCas of 31 Dec 2023 | 653.74k | 0.89% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 611.85k | 0.84% |
| Tang Capital Management LLCas of 31 Dec 2023 | 550.00k | 0.75% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
